multiple Sclerosis and, for the first patient the genoese care and experimental based on the use of mesenchymal stem cells, adult è già the game.
To give the news è Antonio Birds, head of the Centre for multiple sclerosis of the Università di Genova, in the course of the twenty-eighth european Congress on treatment and research in multiple Sclerosis held in Lyon, france.
The trial is called Mesems, and has the objective of verifying the effects produced by the mesenchymal stem cells adult taken from the bone marrow.
Genoa is not; that the first of the 160 patients (thirty will be Italian) that will come in the testing, involving a dozen Countries.
In the project Italy is the country lead and part of the funds have been made available by the Italian Foundation for multiple sclerosis (Sism).
regarding the first patient Bird explains that “the stem cells have been transplanted in September” and now the hope is that the results allow the identification of new treatments.
The goal is ambitious: “We would like to get to get medicines based on stem cells – explain the Birds – which are able to block the disease and repair damaged tissue when possible.”
On its effective functioning, the expert clarifies that the phase II of the trial aims to “provide a definitive answer to the question of whether the mesenchymal stem cells actually work against this disease.”
of Course, it would be a great result but if the results are negative you canà “at least to put an end to tourism in the hope, where it counts only the credit card of the desperate patients in search of miracle cures,” added the scientist.
For each good account of the possible therapy might have of the extent to which the stem can be used on all patients but only in those “who have nerve tissue is still not completely corrupted.”
multiple sclerosis (MS) is an autoimmune disease chronic demyelinating, that affects the central nervous system causing a wide spectrum of signs and symptoms. The disease attacks the nerve cells by interfering così in the communication between the brain and the spinal cord. It is a disease that has a prevalence that ranges between 2 and 150 cases per 100,000 individuals.
On its origins, still there are no certainties, of the epidemiological studies have provided indications about its possible causes, but none of these is è revealed the final.
multiple Sclerosis: new genetic elements
multiple Sclerosis: each year, 1200 new diagnosis, women are twice as
multiple Sclerosis, the experimentation of the method Zamboni
11 October 2012